Chromogranin A (CgA) is the major soluble protein in the core of catecholamine storage vesicles. It is coreleased by exocytosis along with catecholamines from storage vesicles in adrenal medulla and sympathetic axons, and its corelease has been used to document exocytosis as the mode of physiologic catecholamine release in experimental animals and in humans. Its functions may include binding of calcium and catecholamines within the catecholamine storage vesicle core, or generation of biologically active peptides such as pancreastatin. Recently, we have noted overexpression of adrenal medullary and plasma CgA in genetic (hereditary) hypertension - both rodent (the spontaneously hypertensive rat; SHR) and human. The synthesis, storage and release of CgA seem to be augmented in the SHR. The data suggest that overexpression of CgA is heritable in both rodent and human genetic hypertension. Since both human essential and rodent (SHR) hypertension are at least in part heritable, it is important to look for alterations in gene expression to understand the pathogenesis of hypertension. The overproduction of CgA suggests increased CgA gene expression (perhaps at the transcriptional level) in hereditary hypertension. Thus, CgA provides an ideal """"""""window"""""""" for examining the involvement of the genome in hereditary hypertension. We have recently isolated and mapped the rodent CgA gene from mouse and rat cosmid genomic libraries. We have determined the gene's intron/exon structure and the sequence of its 5' regulatory region, and have established its functional promoter/enhancer region by transfection and expression of reporter constructs. Thus, we are poised to dissect apart elements of this gene's transcriptional control region likely to be activated in hypertension. In addition, knowledge of control of this catecholaminergic protein's biosynthesis will give us clues to how the sympathochromaffin phenotype is maintained by the genome within such cells, and how gene expression is activated to govern secretion from chromaffin cells and sympathetic axons. The proposed experiments are designed to characterize the transcriptional control region of the CgA gene and the overexpression of CgA in rodent genetic hypertension, and to identify how the genome of hypertensive organisms is activated to yield this overexpression. Furthermore, we will gain understanding of how the nucleus controls secretory protein synthesis in the sympathochromaffin system.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL046366-01A1
Application #
3365484
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Project Start
1992-03-01
Project End
1995-02-28
Budget Start
1992-03-01
Budget End
1993-02-28
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Eskeland, N L; Zhou, A; Dinh, T Q et al. (1996) Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. J Clin Invest 98:148-56
Cubeddu, L X; O'Connor, D T; Parmer, R J (1995) Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy. J Clin Oncol 13:681-7
Takiyyuddin, M A; Parmer, R J; Kailasam, M T et al. (1995) Chromogranin A in human hypertension. Influence of heredity. Hypertension 26:213-20
Cubeddu, L X; O'Connor, D T; Hoffmann, I et al. (1995) Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies. Br J Cancer 72:1033-8
Wu, H; Mahata, S K; Mahata, M et al. (1995) A functional cyclic AMP response element plays a crucial role in neuroendocrine cell type-specific expression of the secretory granule protein chromogranin A. J Clin Invest 96:568-78
O'Connor, D T; Cervenka, J H; Stone, R A et al. (1994) Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine beta-hydroxylase deficiency. Clin Sci (Lond) 86:149-58
Takiyyuddin, M A; Brown, M R; Dinh, T Q et al. (1994) Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release. J Auton Pharmacol 14:187-200
Garcia, G E; Gabbai, F B; O'Connor, D T et al. (1994) Does chromostatin influence catecholamine release or blood pressure in vivo? Peptides 15:195-7
O'Connor, D T; Cervenka, J H; Stone, R A et al. (1993) Chromogranin A immunoreactivity in human cerebrospinal fluid: properties, relationship to noradrenergic neuronal activity, and variation in neurologic disease. Neuroscience 56:999-1007
Parmer, R J; Miles, L A; Xi, X P et al. (1993) Processing of chromaffin granule proteins: a profusion of proteases? Neurochem Int 22:361-7

Showing the most recent 10 out of 12 publications